CERo Therapeutics Holdings, Inc. Common Stock (CERO) - Total Liabilities
Based on the latest financial reports, CERo Therapeutics Holdings, Inc. Common Stock (CERO) has total liabilities worth $8.45 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CERo Therapeutics Holdings, Inc. Common (CERO) cash conversion ratio to assess how effectively this company generates cash.
CERo Therapeutics Holdings, Inc. Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check CERo Therapeutics Holdings, Inc. Common liquidity resilience to evaluate the company's liquid asset resilience ratio.
CERo Therapeutics Holdings, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of CERo Therapeutics Holdings, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IMAGE POWER S.A. ZY -10
F:7UQ
|
Germany | €280.97K |
|
ARC MINERALS LTD
F:DFYA
|
Germany | €1.77 Million |
|
M.T.I Wireless Edge Ltd
LSE:MWE
|
UK | GBX16.62 Million |
|
Kollect on Demand Holding Ab
ST:KOLL
|
Sweden | Skr10.37 Million |
|
ProstaLund AB
ST:PLUN
|
Sweden | Skr11.30 Million |
|
Upgrade Invest Nordic AB
ST:UPGRAD
|
Sweden | Skr46.00K |
|
Glen Eagle Resources Inc
V:GER
|
Canada | CA$4.08 Million |
|
Founder Group Limited Ordinary Shares
NASDAQ:FGL
|
USA | $104.66 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down CERo Therapeutics Holdings, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CERo Therapeutics Holdings, Inc. Common (CERO) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CERo Therapeutics Holdings, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CERo Therapeutics Holdings, Inc. Common Stock (2021–2024)
The table below shows the annual total liabilities of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.10 Million | -82.83% |
| 2023-12-31 | $47.18 Million | +18.26% |
| 2022-12-31 | $39.90 Million | +331.42% |
| 2021-12-31 | $9.25 Million | -- |
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.